Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Severe Hepatic Impairment and Overt HE
NCT01846663Phase 4Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Apr 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin in hepatic encephalopathy (HE), sponsored by Valeant Pharmaceuticals. Started Apr 2013; status: terminated.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT01846663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01846663.